Indeed, co-targeting of SHP2 using SHP099 and FGFR using FIIN4 inhibitor was shown to decrease primary tumor and metastatic outgrowth in HER2-enriched and TNBC models. This evidence concerns the gene ERBB2 and neoplasm.